Genmab AS's Total Assets for the quarter that ended in Mar. 2026 was $12,376 Mil.
Warning Sign:
If a company builds assets at 65.8% a year, faster than its revenue growth rate of 24% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Genmab AS's average Total Assets Growth Rate was 202.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 108.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 65.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 51.30% per year.
During the past 13 years, Genmab AS's highest 3-Year average Total Assets Growth Rate was 136.30%. The lowest was -55.90%. And the median was 30.80%.
Total Assets is connected with ROA %. Genmab AS's annualizedROA % for the quarter that ended in Mar. 2026 was 1.68%. Total Assets is also linked to Revenue through Asset Turnover. Genmab AS's Asset Turnover for the quarter that ended in Mar. 2026 was 0.07.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Genmab AS's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Genmab AS Total Assets Related Terms
Genmab AS Total Assets Historical Data
* Premium members only.
The historical data trend for Genmab AS's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Genmab AS's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (GNMSF) has a Total Assets of $12,376 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Genmab AS and its competitors.
Is Genmab AS's Total Assets too high?
Genmab AS's current Total Assets is $12,376 Mil. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Total Assets compare to VRTX and REGN?
Genmab AS's Total Assets of $12,376 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Genmab AS and its competitors. Genmab AS's current Total Assets is $12,376 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $337.53, compared to a current price of $275.00 — trading 18.5% below its estimated fair value. The current Total Assets is $12,376 Mil. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Total Assets is $12,376 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (GNMSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of $275.00 is trading 18.5% below its estimated GF Value™ of $337.53.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for GNMSF:
Total Assets: $12,376 Mil
GF Value™: $337.53 vs. price of $275.00 (18.5% below fair value)
No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score
Get the complete analysis for GNMSF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNMSF has been successfully added to your 
